<SEC-DOCUMENT>0001178913-25-002019.txt : 20250530
<SEC-HEADER>0001178913-25-002019.hdr.sgml : 20250530
<ACCEPTANCE-DATETIME>20250530070802
ACCESSION NUMBER:		0001178913-25-002019
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250530
FILED AS OF DATE:		20250530
DATE AS OF CHANGE:		20250530

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioLineRx Ltd.
		CENTRAL INDEX KEY:			0001498403
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35223
		FILM NUMBER:		251006342

	BUSINESS ADDRESS:	
		STREET 1:		2 HAMA-AYAN STREET
		STREET 2:		MODI-IN TECHNOLOGY PARK
		CITY:			MODI-IN
		STATE:			L3
		ZIP:			7177871
		BUSINESS PHONE:		972-2-548-9100

	MAIL ADDRESS:	
		STREET 1:		2 HAMA-AYAN STREET
		STREET 2:		MODI-IN TECHNOLOGY PARK
		CITY:			MODI-IN
		STATE:			L3
		ZIP:			7177871

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioLineRX, Ltd.
		DATE OF NAME CHANGE:	20100805
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2533302.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div style="font-size: 14pt;"><br>
  </div>
  <div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">WASHINGTON, D.C. 20549</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">FORM 6-K</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">PURSUANT TO RULE 13a-16 OR 15d-16 OF</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">THE SECURITIES EXCHANGE ACT OF 1934</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">For the month of May 2025</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">Commission file number: 001-35223</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">BioLineRx Ltd.</div>
    <div style="text-align: center; line-height: 1.25;">(Translation of registrant&#8217;s name into English)</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">2 HaMa&#8217;ayan Street</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Modi&#8217;in 7177871, Israel</div>
    <div style="text-align: center; line-height: 1.25;">(Address of Principal Executive Offices)</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Form 20-F <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Form 40-F&#160;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><font style="font-family: 'Segoe UI Symbol', sans-serif;"> <br>
      </font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">On May 30, 2025, the Registrant issued the press release
        which is filed as&#160;<a href="exhibit_1.htm"><u>Exhibit 1</u></a>&#160;to this Report on Form 6-K.</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
      </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
      by the undersigned, thereunto duly authorized.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z8703fd7ff2e14ddea0113e5ab31d1c37" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 1.99%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 33.33%; vertical-align: bottom;" colspan="2">
            <div style="line-height: 1.25; font-weight: bold;">BioLineRx Ltd.</div>
          </td>
          <td style="width: 64.69%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 1.99%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.48%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 29.85%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 64.69%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 1.99%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.48%; vertical-align: top;">
            <div style="line-height: 1.25;">By:</div>
          </td>
          <td nowrap="nowrap" style="width: 29.85%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">/s/ Philip A. Serlin</div>
          </td>
          <td style="width: 64.69%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 1.99%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.48%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 29.85%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Philip A. Serlin</div>
          </td>
          <td style="width: 64.69%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 1.99%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.48%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 29.85%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Chief Executive Officer</div>
          </td>
          <td style="width: 64.69%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">Dated: May 30, 2025</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exhibit_1.htm
<DESCRIPTION>REGISTRANT'S PRESS RELEASE DATED MAY 30, 2025
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div style="text-align: right;"><u><font style="font-weight: bold;">Exhibit 1</font></u><br>
  </div>
  <div>
    <div class="BRPFPageHeader">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;"><img width="164" height="38" src="image0.jpg"></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">For Immediate Release</div>
    <div style="line-height: 1.25; font-size: 12pt;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;"> in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-style: italic;">&#8211; 4 of 11 PDAC patients in the pilot phase remained progression free at over one year &#8211;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-style: italic;">&#8211; Poster presentation on Saturday, May 31<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> &#8211;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;"><font style="font-weight: bold;">TEL AVIV, Israel, May 30, 2025 &#8211;</font>
      BioLineRx Ltd. (NASDAQ/TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare disease, today announced that a poster including new data from the single-arm pilot phase of the
      investigator-initiated, randomized CheMo4METPANC Phase 2 combination clinical trial will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3, 2025 in Chicago, Illinois.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">The CheMo4METPANC trial is evaluating the company's CXCR4 inhibitor motixafortide, the PD-1 inhibitor cemiplimab, and standard-of-care
      chemotherapies gemcitabine and nab-paclitaxel, versus gemcitabine and nab-paclitaxel alone, in first-line pancreatic cancer (PDAC).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">Updated results from the pilot phase indicate that four of eleven patients remained progression free after more than one year. Two patients
      underwent definitive treatment for mPDAC: one had complete resolution of all radiologically detected liver lesions and underwent definitive radiation to the primary pancreatic tumor, and one had a sustained partial response and underwent
      pancreaticoduodenectomy with pathology demonstrating a complete response. An analysis of pre- and on-treatment biopsies and peripheral blood mononuclear cells (PBMCs) also revealed that CD8+ T-cell tumor infiltration increased across all eleven
      patients treated with the motixafortide combination. In addition, patients achieving a partial response were found to have higher pre-treatment proportions of CXCL12-producing cancer associated fibroblasts, a potential marker of response.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#8220;The data that continue to emerge from the pilot phase of the CheMo4METPANC Phase 2 study are extremely encouraging, with four of eleven
        patients remaining progression free after more than one year, as well as two patients that underwent definitive treatment, in what has historically been among the most challenging tumor types to treat,&#8221; stated Philip Serlin, Chief Executive Officer
        of BioLineRx Ltd. &#8220;Notably, these results further suggest that the combination of motixafortide, cemiplimab and standard-of-care chemotherapy can overcome the immunosuppressive mechanisms of the tumor microenvironment (TME) and increase
        intratumoral CD8+ T-cell infiltration, resulting in improved patient outcomes. We look forward to results from the ongoing randomized portion of this important study.&#8221;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25"> <br>
      </div>
    </div>
    <div style="line-height: 1.25;">The pilot clinical trial of motixafortide, cemiplimab, gemcitabine and nab-paclitaxel (N=11) demonstrated an overall response rate (ORR) of
      64% (7/11) and a disease control rate (DCR) of 91% (10/11), compared to historical ORR and DCR of 23% and 48%, respectively, with gemcitabine and nab-paclitaxel. Based on these encouraging results, the CheMo4METPANC Phase 2 trial was amended to
      become a randomized study, with planned enrollment increasing from 30 to 108 patients. The trial is the first large, multi-center, randomized study evaluating motixafortide with a PD-1 inhibitor and first-line PDAC chemotherapies. The trial is
      planned to be fully enrolled in 2027, and a prespecified interim analysis is planned for when 40% of PFS events are observed.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25; font-weight: bold;">Poster Presentation at ASCO 2025<br>
        McCormick Place,&#160;Chicago, Illinois</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25; font-weight: bold;">Poster Session Details</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;"><font style="font-weight: bold;">Primary Track:&#160;</font>Gastrointestinal
        Cancer&#8212;Gastroesophageal, Pancreatic and Hepatobiliary</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;"><font style="font-weight: bold;">Title:</font>&#160;CheMo4METPANC: Combination
        Chemotherapy (Gemcitabine and Nab-Paclitaxel), Chemokine (C-X-C) Motif Receptor 4 Inhibitor (Motixafortide), and Immune Checkpoint Blockade (Cemiplimab) in Metastatic Treatment-Na&#239;ve Pancreatic Adenocarcinoma</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><font style="font-weight: bold;">Presenter:</font>&#160;Gulam Abbas Manji, MD,
        PhD,&#160;Columbia University Herbert Irving Comprehensive Cancer Center<br>
        <font style="font-weight: bold;">Abstract:</font> 4167<br>
        <font style="font-weight: bold;">Poster Bd #:</font> 457<font style="font-weight: bold;">&#160;</font><br>
        <font style="font-weight: bold;">Date:</font> May 31, 2025<br>
        <font style="font-weight: bold;">Time:</font>&#160;9:00am CDT<br>
        <font style="font-weight: bold;">Location:</font>&#160;Hall A</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><font style="font-weight: bold;">About CheMo4METPANC Phase 2 Clinical
          Trial</font><br>
        The multi-center CheMo4METPANC Phase 2 clinical trial (<u>ClinicalTrials.gov</u> Identifier: <u>NCT04543071</u>) is a randomized, investigator-initiated clinical trial in first line metastatic pancreatic cancer. Sponsored by&#160;Columbia University, and supported equally by&#160;BioLineRx&#160;and Regeneron, the study is
        evaluating the combination of CXCR4 inhibitor motixafortide, PD-1 inhibitor cemiplimab, and standard of care chemotherapies gemcitabine and nab-paclitaxel, versus gemcitabine and nab-paclitaxel alone, in 108 patients. The trial's primary endpoint
        is progression free survival (PFS). Secondary objectives include safety, response rate, disease control rate, duration of clinical benefit and overall survival.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25"> <br>
      </div>
      <div style="line-height: 1.25;"><font style="font-weight: bold;">About Pancreatic Cancer</font><br>
        Pancreatic cancer has a low rate of early diagnosis and a poor prognosis. In&#160;the United States&#160;in 2024, an estimated 66,000 adults will be diagnosed with the disease, which accounts for approximately 3% of all cancers in the&#160;U.S.&#160;and about
        7% of all cancer deaths.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup>&#160;Worldwide, an estimated 496,000 people were diagnosed with the disease in 2020. In the&#160;U.S., if the cancer is detected at an early stage when surgical removal of the tumor is possible, the 5-year relative
        survival rate is 44%. About 12% of people are initially diagnosed at this stage. If the cancer has spread to surrounding tissues or organs, the 5-year relative survival rate is 15%.&#160; For the 52% of patients who are initially diagnosed with
        metastatic cancer, the 5-year relative survival rate is 3%.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2&#160;</sup>In particular, hepatic (liver) metastases are a critical risk factor driving poor prognoses for patients with metastatic PDAC. These data highlight the need for the development
        of new therapeutic options.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;"><font style="font-weight: bold;">About Motixafortide in Cancer
          Immunotherapy</font><br>
        Motixafortide inhibits CXCR4, a chemokine receptor and a well validated therapeutic target that is over-expressed in many human cancers including pancreatic ductal adenocarcinoma (PDAC).&#160;Motixafortide leverages the expression of the CXCR4
        receptor on different immune cells and potentiates the immune system against the tumor. Among CXCR4-expressing immune cells, some exhibit anti-tumoral activity, such as effector T cells and some exhibit pro-tumoral activity and support tumor
        growth. By blocking the CXCR4 receptor, motixafortide was shown in a Phase 2 study in pancreatic cancer patients to enhance anti-tumoral activity and to ameliorate the pro-tumoral activities by modulating the effector/suppressor cell ratio towards
        a proinflammatory profile.</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About BioLineRx</div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare disease. The
        Company's first approved product is APHEXDA&#174; (motixafortide), with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, which is being developed and commercialized by Ayrmid Ltd. (globally,
        excluding Asia) and Gloria Biosciences (in Asia). BioLineRx is utilizing its end-to-end expertise in development, regulatory affairs and manufacturing to advance its innovative pipeline and ensure life-changing discoveries move beyond the bench to
        the bedside.</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;">Learn more about who we are, what we do, and how we do it at&#8239;<u>www.biolinerx.com</u>, or on&#8239;<u>Twitter</u>&#8239;and&#8239;<u>LinkedIn</u>.&#8239;&#160;</div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Forward Looking Statement</div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic;">Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking
      statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects,"
      "should," "will," and "would," and describe opinions about future events. These include statements regarding management's expectations, beliefs and intentions regarding, among other things, the potential success of the license agreement with Ayrmid
      and the commercial potential of motixafortide, expectations with regard to clinical trials of motixafortide, the expected cash runway, and BioLineRx's business strategy. These forward-looking statements involve known and unknown risks, uncertainties
      and other factors that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could
      cause BioLineRx's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the clinical development, commercialization and market acceptance of BioLineRx's therapeutic
      candidates, including the degree and pace of market uptake of APHEXDA for the mobilization of hematopoietic stem cells for autologous transplantation in multiple myeloma patients; the initiation, timing, progress and results of BioLineRx's
      preclinical studies, clinical trials, and other therapeutic candidate development efforts; BioLineRx's ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials, whether
      the clinical trial results for APHEXDA will be predictive of real-world results; BioLineRx's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; whether access to APHEXDA is
      achieved in a commercially viable manner and whether APHEXDA receives adequate reimbursement from third-party payors; BioLineRx's ability to establish, manage, and maintain corporate collaborations, as well as the ability of BioLineRx's collaborators
      to execute on their development and commercialization plans; BioLineRx's ability to integrate new therapeutic candidates and new personnel as well as new collaborations; the interpretation of the properties and characteristics of BioLineRx's
      therapeutic candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx's business model and strategic plans for its business and therapeutic candidates; the scope
      of protection BioLineRx is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of
      BioLineRx's expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive
      companies, technologies and BioLineRx's industry; BioLineRx's ability to maintain the listing of its ADSs on Nasdaq; and statements as to the impact of the political and security situation in Israel on BioLineRx's business, which may exacerbate the
      magnitude of the factors discussed above. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 31, 2025. In
      addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any
      forward-looking statements unless required by law.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Contacts:</div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;"><u>United States</u></div>
      <div style="text-align: justify; line-height: 1.25;">Irina Koffler</div>
      <div style="text-align: justify; line-height: 1.25;">LifeSci Advisors, LLC</div>
      <div style="text-align: justify; line-height: 1.25;"><u>IR@biolinerx.com</u></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;"><u>Israel</u></div>
      <div style="text-align: justify; line-height: 1.25;">Moran Meir</div>
      <div style="text-align: justify; line-height: 1.25;">LifeSci Advisors, LLC</div>
    </div>
    <div style="text-align: justify; line-height: 1.25;"><u>moran@lifesciadvisors.com</u></div>
    <div style="text-align: justify; line-height: 1.25;"><u> <br>
      </u></div>
    <div style="text-align: justify; line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><u> </u></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !C :0# 2(  A$! Q$!_\0
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M_P#)2X__ +$F(_\ 4[+SY+Q@_P"2;P7_ &.</_ZAXX_J\_X-5/\ E'K\8_\
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MF\%_V.</_P"H>./ZO/\ @U4_Y1Z_&/\ [/+^(/\ ZI+]GFOZ9*_F:_X-5/\
ME'M\9/\ L\OX@_\ JDOV>?\ //\ *OZ9:^2X\_Y+#/\ _L.?_IJF?5<"?\DA
MD'_8!#_TNH?Y 'Q[_P"2Z?&G_LK/Q&_]3#6:_P!(/_@@K_RB6_9!_P"P+\5O
M_5\_%.O\WSX]_P#)=/C3_P!E9^(W_J8:S7^D'_P05_Y1+?L@_P#8%^*W_J^?
MBG7[=XS?\D7PU_V,,%_ZJ<4?AO@K_P EMQ9_V"8O_P!6U(_7PG')X Y)/:O\
MO7_@L9^VQK?[;_[<?Q4\81:D9_A=\,M:U;X1?!G3;35)-1T5?!/@S6+[3I/%
ME@5V6AN?B)J\5[XQNKB&$2BSU+2M(EN;RWT6SGK_ $H_VC_$-[X1_9X^//BO
M3I'AU#PQ\&/BCXAL)49D>*\T7P/KFI6LB.GS(Z3VR,K+\RD CD"O\@ZO!\",
MIP]?'YWG%6"EB,OI83"81N_[OZ]]9EB*BUMS^SP\*:=F^2I42:N[^YX_9MB<
M/EF19/2DXX?,\1C,5B[-+VBRY818>E+W6W#VF+=5I22YZ5-M2LN7^H__ ((%
M_P#!&[P?^U9;G]L7]J+1(]?^!GA[Q#>Z+\*_A?>$'2_BMXGT"=[77/$'C&,?
M/<^ ?#&IJ=+M]"1T7Q7XDM-0MM89= T2\TOQ+_=MHVBZ/X<TK3]!\/Z3INA:
M'I%I#8:5HVCV-KIFE:98VR".WL]/T^RB@M+.U@C 2&WMX8XHT 5$ &*^1?\
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M_LIVG_\ J#>$:_U(*_RW_P#@MA_RE4_;1_[*=I__ *@WA&OS'P;_ .2EQ_\
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MZE*=*='ZQ@JU&--PJTZCDJTZ<XN#E'^OK_B$?_ZR!_\ FJ7_ .4E1_Q"/_\
M60/_ ,U2_P#RDJ_<#_@DE_P5 ^'7_!1'X": ^HZ_HNE?M->!-#LM.^-?PX,]
MM9:G<:C8I#8R?$?PSI82W^V>"_%DQBU -IL4UOX7U6]E\-7[J]O876H_K97Y
MCF7B1XFY1CL3EV89Q/#8S"594JU*IE.2)J4=I1?]FVG3J1M.E4BW"I3E&<).
M,DW^HY;X9>%V;X'#9EEV2T\5@\92C6H5J><9XXRC);27]IWA4@[PJTY)3I5(
MRIU(QG&27\:?_$(__P!9 _\ S5+_ /*2H_XA'_\ K('_ .:I?_E)5_997/\
MBOQ9X8\">&=>\9^-?$.C>$_"/A?2K[7?$?B7Q%J5IH^AZ%HVF6\EWJ&J:KJE
M_+!9V-C9VT4D]S<W$T<44:,SL *XH^+'B%)J,<^<I2:C&,<IR5N3;LDDLMNV
MWHDM6SM?A#X=)-OAZR6K;S?/$DENV_[3/X\_^(1__K('_P":I?\ Y25?TL?\
M$]/V/E_8,_9(^&'[+0^(9^*A^'%SX[N6\=GPG_P@XUIO&OQ"\5>.]J^%_P#A
M)?%_]F#3%\2KI.3XBU WIL3J'^B"Z%C;=[^RO^U[^S_^VA\/-1^*'[.WCRR\
M=^$](\7>(O!6JSQ0S6.HZ9KGAW4);1DU'2KQ8[^QM]9L!9>(_#\UU#$=4\.:
MMI>I(D9N'AA^EZ\GB3C'B_.Z/]D<28ZK5AA,7&O+!ULNP.!JT<72IUJ*=18?
M!X:O&4*=>K%TYRY??NX.48M>OPUP5P=D%=YOPUE].A5Q>#EAEBZ68YAC:5;"
M5:M&NXP^LXW$T'&53#T9JI"//[EE-1E)2\]^+G_)*?B=_P!D]\:?^HWJ5?FI
M_P $5O\ DRV/_LJ_CS_T1H%?I7\7/^24_$[_ +)[XT_]1O4J_-3_ ((K?\F6
MQ_\ 95_'G_HC0*^IR7_DRW'O_9<<!_\ JNXM/A>(/^4@_#+_ +-AXL_^K_PM
M/UMHHHK\E/VT***\;^/GQS\"?LY?"OQ3\6OB)?&UT'PW9EH;.%HO[2U_6)U=
M=*\.Z-%*Z)<:MJ]THM[5&988E\V[NI(;.VN)X^K X'&9GC<)EV7X:MC,=CL1
M1PF#PN'@ZE;$8G$5(TJ-&E".LIU*DHQBEU9Q9CF.!RC+\;FN:8NA@,MRW"8C
M'8_'8JI&CAL)@\+2E7Q.)KU9M1ITJ-*$ZE2<G:,8MGS9^WS^V%%^R[\.M/T7
MP79_\)3\?/BM=?\ "*?"/P596_\ :FH/JM_(E@/$EWH\#_;;NPT^[N;:STVS
M@AFFUOQ%=Z=I4,+V[:C/9_E5X8^$'QR_X)0>(_AY^U!XOOE^)?@'XH6*>'/V
MK-.T/2(I[OP-K7B/6I=7L;C1[BVD:2]CL+F>UMK?5(H[?3]5U^SU'26AMD\2
M^'5M/LC]@WX&^/\ XU?$;7?^"@W[3=@Z^.O'N1\"? UW-<W&G?#GX=2VHATW
M5=/L[F7;927]E-);:);M:0S?9FO_ !;<^9JWBIWM/U>\:>#O#/Q#\)^(O WC
M+2+37O"OBO2+W0]>T>^C\RVO]-U"%H+B%QPR/M;?#/&R36TZ1W$$D<T4;K^\
M/BG)/"_E\/L-@\'Q)@,8U1\7,53E3J1SS$2A*F\@R'&IMX6APC*K6J8+,J%2
M'U[B&G/%5$\#0H4JG\U?ZD\0^,C_ .(I8S'YAPAFF76Q?@5@JL<11GPSAH35
M5<4<4Y;STOKV+X]HTZ6&S;(L723ROA"O'*E['-\5CZU*3PCXM\.>//"_A_QK
MX/U>TU_PMXJTBPU[P_K-@[/::EI6IV\=U97<.]4D02PR*6BFCCG@?=#/%',C
MQKT5?AC^SMXP\3?\$V/V@E_8\^+^L7M_^S1\4=5O-6_9T^)^N2@6WAS4]2O0
M9O#.NZFUK!;QO?7US!:^(AY\=II>OW-AXD2UM-,\5ZA<VW[G YY'(/(([U^8
M<;<)/A7,J'U/%?VKPYG.&6:\+Y["*5+-<HJSE&G*HHZ8?,L'-2P>;8"?+6P6
M-I5*<H>SE1G4_8O#OCA<:Y1B?K^">2<6\/8QY'QIPU5FY5LBS^A2IU*L*4Y6
M>+RC,:-2GF60YI"]',LJQ.'Q$7&JJ]&B4445\8?H 4444 ?(_P"V]^QE\(OV
M\OV>_%O[/OQAL9!I>L^7J_A3Q581Q-X@^'WCK38+E/#WC7PY+*-JW^FM=7%M
M>V;LMMK6AWVJZ#?YL=3N!7^:)^W?_P $]_VB_P#@GO\ %6Y^'7QO\,2'0=2N
M[YOAU\4M$AN+GP!\2]&M&C;[?X>U5XT^S:I:PW%M_;OAC4EMM=T*>:/[3:R6
M%SIVHW_^KG7!_$KX6_#;XR^#M7^'OQ9\!^$OB1X'UZ$P:OX4\:Z!IOB/0KY,
M'8TVG:K;W-N)X6/F6UTB)<VLP6>VEBF17'Z)P+XB9EP95G0]G_:&3XB?M,1E
M\JCIRI56E%XG!U&IJE6<8Q52$H2IUXQC&7)-0JP_.>/?#G+.-Z-.M*J\OSG"
MT_9X;,84U44Z/-*:PN,I7@ZU!2E.5-QG"K0G.4X2E"52E4_S3_V-?^"VG[?7
M[$GA:P^'GP]^(.@_$7X7Z-9)8>'/AK\:]$OO&OAKPK;1R-)';>&+_3=;\->,
M=#TZ$.\<&AV'BJ+P_;(Q^SZ3$X#C]9Y/^#L?XZ'PD;.']D/X31^.OL?ECQ')
M\1/&$OA,:AY0'VH^"UT>'6#9^=F3[#_PGHF\HB+^T=P\X_JM\?O^#9/_ ()_
M_%CQ!<^)?AGK'Q<_9VN+J%4D\,^!/$&F>)O GVKS'>2_BT7Q[I6O^(+.:8,(
MWL].\76.CQ)'']DTRV;S&D^)E_X-*_"(\3&X?]N'Q(W@[.X:0OP$TQ?$V,8\
MH^(C\6'TO(/S>?\ \(M@CY/LP_UE?IE?B7P5SZ;Q^:Y5+"8RIS5ZT7@<?AZE
M2N]9*J\GJNA7J5)*[G5;C-MRJ2C*4S\QH\->.&0Q^H95G5/&X*#A0HU'C<OQ
M4*=!7Y)06=4'B*$*:ERNG23E%*,*49TX4VOP(_;-_P""T/[>W[<.@W_@;XF?
M$K2O WPKU:SM[36?A/\ !S1)?!/@S7O(N6NFD\0W=YJ?B#QMXAAN)!:B;1]<
M\8:AX=4V%K-;:-;W1N9[GR']@+_@G%^T9_P40^*-MX(^#OAV;3O!6E:A9I\2
MOC#KMI<1^ _ASI,KQO<2WUZ/*&M^)9;1C)H?@S2IGUG6)C')+_9FBQZCK>G?
MV<_L_?\ !LU_P3Y^$6NP^)/B5>_%?]HV[@B40>'_ (B>([#P]X&ANDDWK??V
M#\/M,\,ZQ?2@ 1FRUKQ1JVCR(6\[3)6(9?WO^'OPW^'WPD\(Z/X!^%W@CPI\
M._!.@6R6FB^$_!>@Z9X;\/Z9;HH4)::5I%M:6<3/M#2R"+S9Y"TLSR2,SGFS
M3Q:X>R7+JN5\!9-'"RJ+3&3PM+!X:E.44I5XX>+E7QF(4?=53%.E::C*7MH1
MY)=&5>$'$.>9A1S7Q!SRIC(TV_\ 8:6*K8S$5*<9-QH2Q4^6A@L/*;<Y4L)&
MI>#:C*A4FY0\/_8T_9"^$7[#GP \'?L]_!C3)+7PWX:2?4-9UR^(EU[QMXPU
M7RY?$7C/Q)=99KC5=8N8XUCA5S::/I-KIF@:7';Z1I-A:P_4M%%?S]B,17Q>
M(K8K%5:F(Q.(JSKUZ]63G5K5:LG.I4J3E=RG.3<I-N[;/Z&P^'H82A1PN%HT
M\/AL/2IT*%"C"-.E1HTHJ%.E3IQ2C"$(1481BDHQ225C_,G_ ."]W_*6O]KW
M_L+?"/\ ]4!\*:_I$_X-2?\ DSC]HO\ [.8F_P#56_#^OIG]LK_@WL_9L_;3
M_:4^)O[3?CSXV_''PIXL^*-UX:NM6\/^$?\ A AX>TYO#'@SPYX)LUTX:SX3
MU/4L3Z?X:M+NY-S?3DWD]P8O+@,<4?W9_P $X_\ @G)\,O\ @FM\+_'7PJ^%
MOCKQWX]T;QYX]/Q!U#4/'X\/_P!IV6IMX>T;PXUE9MX=TC1K4V'V71+:=1-;
M27 N)9R9VC:../\ :N)N.^'\T\.<KX:PE;$RS3"8+(:%:$\+4A153+\/0IXE
M1K/W9)2A)0:^.UUHT?B'"_ /$65>)6;\3XRCA8Y5C,;Q!7H5(8J$ZSIYCB:U
M7#.5%+FBY0G'G3^!Z/8_0^OR"_X*^?\ !*WPE_P4I^"]JNA7NE^#?VD/A?:Z
MC>?!SQYJ23+I%^EWLN-2^'7CA[2*>[/A'Q+-!$T&JVUO=ZAX0UL0:]8VFI63
M:YX?U[]?:*_'LKS/'9-C\+F>75Y8;&8.JJM&K'6S5U*$XN\:E*I!RIU:<TX5
M*<I0FG&31^S9GEN"SC 8K+,QH0Q."QE)T:]&:TE%M.,HO>%2G-1J4JD;2IU(
M1G%J44S_ "$/CO\  #XV_LL?%#6/A+\=/ /B3X7?$CPU(DUQHVM1+$\]JT\\
M-GKOA_5[*:XTKQ!H%[-:7(TOQ'X?U#4-'OVMYOL5_,T$H3]??V:_^#C/_@HS
M^S]X?TGP?XD\0> /VBO#>EW-E'#<?'#P_K&J>-H-$MUMX9])MO'?A+Q'X3U>
M_N)88I7M]:\91^,=2@NY_-N'OK2*.P']^'[1/[*?[.G[6?@]? G[1GP?\%_%
MCPY!*;G3HO$VF;M5T*\:-XFOO#7B.QDL_$?AF_>&66![[0-5TZZD@EEMY)7@
MEDC;^?SXN?\ !JW^QSXKU#6]4^$?QO\ CE\(6U*YFN=,T'5/^$6^)GA3PZLO
M,=AI]OJ.G>'/%UYI]N>(AK/C;4=29>)]4F;YQ^_T/%'@KB?!T<-QQD48XFA%
M-5XX9XW"\\DHU9X:=.2Q^$]I\3HKVJLDI5ZDHQO_ #UB/"KC?A;&UL3P'Q!)
MX7$5-<-4Q/U+$J$;RI1Q-.<9Y?C?9:P5:2I3O*\:$8SGR_G;XU_X.P?VBM0\
M/W-I\/?V4_@SX3\42- +76_%OC'QKX[T6VC$X:Z\SPYI,7P_N[B:6UW16LG_
M  DD,5M<E;F:WO8E-F_X9_MH_P#!2_\ ;#_;WU.*3]H3XHW&H^$-/U!-4\/_
M  K\)V:>%OAAX<O8[8VT=W8^&;.2634]1CCDN?*UKQ3J/B'7H$O+JWAU2.SD
M%LG]*OAK_@TG\,6NK0S>,/VZ]>US0U#"XT[PU^SMI_A75IF.W8T.LZI\:/&5
MG;A?G#*^@W1?*D.F"#^F'[,?_!NK_P $YOV>=5_X2/Q3X2\6_M*^(H[BVN+%
M_CWJVDZYX5TIH I>*V\!>&-#\+^%-7M;J10]Q;^--/\ %JX'E0F&%YHY=Z'%
MW@[PO)XO(,K>-QM-<U"I1P..J5H5)67[O%9Y*%3#M**O.EK&+GR*3G.,L:W"
M'C1Q5!83B'-XX# U?W>(I5,;@:5*=**D[5<+D,)4\4I\[7)6;4VH>U<53IN/
M\E/_  2F_P""-WQN_P""A/C;0?&_BC2M7^&O[*6B:S:W'C+XG:K8W5C<^.K&
MQNS_ &EX0^$\5Q'$->UB_:VFTG4/$\3/X?\ "!>XN[N;4M8LK?PUJ7^C[\-?
MAQX(^#_@#P=\+?AMX=T[PEX"\ ^'M,\+>$_#FE1>38Z1HFD6L=I96L0)9Y7$
M<?F7%U.\EU>7+S7=W--<S2ROU6FZ;IVC6%GI6D:?9:5I>G6\5II^FZ;:06-A
M8VD""."UL[.UCBM[:WA0!(H88TCC0!44  5=K\>XTXWS3C/&PKXM1PN!PW,L
M#EU*<ITL.IVYJE2;477Q-1)*=9P@N5*-.G3C=/\ 9>">!LJX)P$\/@G+%8W$
M\LL?F5:"A6Q4H7Y(0@G)4,-3YI>SH1G.SDY5*E2;Y@K_ "W_ /@MA_RE4_;1
M_P"RG:?_ .H-X1K_ %(*_P M_P#X+8?\I5/VT?\ LIVG_P#J#>$:^G\&_P#D
MI<?_ -B3$?\ J=EY\[XP?\DW@O\ L<X?_P!0\<?U=_\ !JI_RCV^,G_9Y?Q!
M_P#5)?L\_P">_P#2OZ9:_F;_ .#53_E'K\8_^SR_B#_ZI+]GFOZ9*^2X\_Y+
M#/\ _L.?_IJF?5<"?\DAD'_8!#_TNH?Y 'Q[_P"2Z?&G_LK/Q&_]3#6:_P!(
M/_@@K_RB6_9!_P"P+\5O_5\_%.O@;QC_ ,&MW[)7C3Q=XI\8ZC^T/^T7;:AX
ML\1ZYXFOK:R_X5HMG;WFO:G=:I=06BS^"9YUMHI[IXX%FGFE$2H))9'RY_=G
M]C;]ESPG^Q;^S7\,OV9/ WB+Q%XL\*?"ZU\26FD>(/%@TW_A(=1C\2^,O$7C
M2Y;4?['LM.TW?;WOB2YM(#;64"FUMX#(K3>8[??^(_'.0<2\-Y-EF55L34Q>
M"Q>&K5XUL+4HP4*6 KX>;C.6DFJM2*26ZN]D?GWAKP+Q!PQQ+G^:9K2PT,)F
M&'Q%/#2HXF%:;E4Q]/$1YX15X+V<6VWL]#4_:]_Y--_:@_[-W^-?_JM?$U?Y
M%]?[#WQ1\"67Q2^&?Q$^&6I7UUIFG?$7P+XN\"7^I6*127NGV7B[0-0\/W5]
M9QSAH'NK2#4)+BW296B:6-%D!0D5_,G_ ,0HG[*'_1S/[0W_ ( ?#;_YEZQ\
M*.-LAX2H9W3SFMB*4L=6P,\.J&&J8B\:$,5&IS.'PV=6%K[Z]C7Q<X(S_C&I
MD,LDI8:HLOAF2Q/UC$PP]GBI8%TN3G^._P!7J<UOALNY_0U^Q[_R:1^RU_V;
MG\$?_59^&*^C*X/X6> [+X5_#'X<_##3+ZZU33?AQX#\(> M/U*^2*.^U&Q\
M'^']/\/6E]>1VZK EU=P:='<7"0*L*S2.(U"!17>5^.UYJ=>M..L9U:DHNUK
MQE-M:=-&?LU*+A2IQ>\80B_512?XH****R+/\@S]HS_DX3X[_P#99?B?_P"I
MOKE?Z+7_  ;Z?\HBOV3/]_X\_P#K2_QDKX;\<_\ !K?^R[X\\:^,/'&I?M(_
M'RSU'QGXI\0>*[^TL=/^'@LK6]\1:M=ZO=6]H)_#DTXM8)[R2*W$TTLHB5/,
MD=\L?W2_8E_9/\)_L/?LQ_#3]E[P/XF\1>,?"_PR/C,Z9XC\5QZ;%K^H_P#"
M:>/_ !5\0;W[>FD6MEIR_9-0\5W=C:_9[:/-G;6YEWSF21OW'Q%X[X>XDX3R
MG*,KK8FIC<'C\!B*T:N%J4::IX?+<;AJC52>DFJM>FDEJTW+9,_"O#C@'B+A
MKC#.<YS2CA88''8#,</0E1Q5.M4=3$YI@<724J<5>*=&A4;;T4DH[L^JZ_EG
M_P""YW_!$/6OVH-4U/\ :]_9'T73W^.46G22_&#X6QLMB_Q@L](TZ*+3O%'A
M&5F6SC^)%A964>EWVCW(@@\;67V*6WO;/Q#IAM_%']3%%?E/#_$&9\,YG1S7
M*JWLL12O"<)IRH8FA-KVF&Q%.Z]I1J65U=3A.,*M*4*L(3C^M<0\/Y9Q/E=?
M*,VH>VPM:THRBU"OAZ\+^SQ.&JM2]E7IW?+*SC*$ITJD9TJE2G+_ !^?#/BG
MXQ_LW?%2V\0>%]6\>_!;XR?#37KF&.\LWUGP5XZ\'>(+!Y;+4-/O('6QU73+
MN/-QI^K:5?0H)H)+G3]1M9()9X'_ 'J^!_\ P<\_M_\ PVL= T/XG^&O@I\>
M])TJ'[/J>L^)O#.L^#OB%KD2*PA>7Q%X*UW3O"=O>(3&)+MOA[=M<QQDSHUS
M(]T?[./VLO\ @FY^Q9^VU$9_VAO@5X6\4^*8[(6%E\1='^V>#_B586\99[2"
M/QOX7N-*UV_LK&9WN+32-;NM5T..66??IDD=U=1S?A)\1_\ @T^_9SU6";_A
M4G[5GQI\"W;R;H9/B%X0\$?%&S@C,BL8C:^'C\([F7$>^-'.H*P8I(_F;623
M]W7B/X<\5T*7^N.1>PQT*<:4Z\L)+%Q46I<WU;'8-QS&G2C*4Y^R<(^S<DX2
MJ3O)?@?_ !#7Q)X1KU?]2N(%B<!.<JT,/]9AA)N:LU]8P&-C5RVI5E&,*?MU
M4?M5%JI"C3M$^+_&O_!V'\?]0\/RVOP]_9+^$/A3Q0T2+'K?B[QWXQ\=Z)%+
MYKF67_A'-(L/A]>.# 42&-O$V(YU:>1IXG%JGXC_ +:7_!5#]M7]O3=I7QW^
M*<B_#Y+ZUU&Q^$7@.P'@_P"&5C>V8?[+=2Z%:SW.H>(;NUDDEFM+[QAK'B._
MLI)6^QW5O&$C3^C_ ,'_ /!I7X0M-46;Q_\ MQ>)/$.B 2*^F^#_ (":7X.U
M1R)?W4BZWK7Q8\=6D0:$9D@/A^79*^%N'2/,OZC?LJ_\&^'_  3I_9CU:'Q3
MJG@;Q)^T5XSL]0AU'2M:_: U72_%&CZ') L&RWTWP%X?T3POX#OK<7$"WL<W
MBOP]XGU2WN6<6NI06Q%NJI\6>#O#,I8O(<HEC\;2][#SA@\;4FJDDM:>)SR:
MGAN6UI5*<.>*YG3A/F:E4^$O&?BF,<'Q#G<<MP%92AB8/%8""=)<WNU,-D4(
MT\5[2^E.K5Y)*WM)1Y4E^&7_  ;2?LH_MPZ+\9;[]IG1)KOX4_LE^(O#\NB^
M-$\9:/<O;?M!"U6_'AZS\":++/874B>$]6O+C4HOB6&72--D?4= TW_A()-0
M\0:;9_W'U7M+2UL+6VL;&UM[*RLX(K6TL[2&.VM;6V@18H+>VMX52*""&-5C
MBBB18XT5410H JQ7XGQ;Q+B.+,ZQ&<XC"X;!RJPIT84,/'X:-&/)2]M6:4\3
M74+1G7FDVHQA"%.E"G3A^X<)<-4.$LCPV2X?%XK&PH2J5)U\5-MRJUGSU50I
M)N&%P_/=T\/3;4+RE.=6M.I5GY[\7/\ DE/Q._[)[XT_]1O4J_-3_@BM_P F
M6Q_]E7\>?^B- K]4/%&A0^*/#7B+PS<3R6L'B+0M6T*>YA57FMX=7L+C3Y)X
ME?Y&DA2X:1%?Y2R@-P37@7[)G[,/AO\ 9(^$X^$OA3Q)KGBK25\3:SXF75/$
M,-A#J(N-:CL4FMF7388+8PPFQ5HF$2OB0A]VT$^WEG$&68;PUXKX:K5:BS;-
M>*.%<TP5%4:DJ<\'E6#X@HXR<ZZ7LZ<X5,PPRA3DU*HI2<4U!GR^;<,9MB_%
MS@GB^C2I/),CX(X^R/,*TJ].-:&8<09MP-B\MA3P[?M*M.I1R',75JQ7+2E"
MG&>M6)]-4445^?GZ:9^K:MIF@Z7J6MZU?VFE:/H]A=ZIJNIW\\=K8Z=IUA!)
M=7M]>7,K+%;VMK;123SS2,J1Q(SL0 37X7>%-.U7_@JU^T[#\1/$FF7T?[#?
M[/&LO%X(T/5K2>TM_B[XY1'62^N+2ZL[>>2WNHS#/XCMKLYTGPRVF^&$@2_\
M3:_=6_Z1?ME?LX>/OVIOAW9?"GPW\9&^$7@S4M6@NOB+_9_A-_$&M^-=$M66
M2'PQ%J!\1:+#HVE27 %[?XM-0DU"YM;""?\ XE::CI^J>^?"CX6^"O@K\//"
MGPO^'ND1:+X2\'Z5;Z5I=J@C,\WEC==:EJ,\<<7VW5]5NVFU#5;]T$M[?W-Q
M<R -)@?IW#7$&3\%\-XS.<KQ:Q?B#G/UO*<OE"CB:<>"LGG35+&YK2Q%:A3H
MUN(,WIU)X3+:N!K5EE."^LXB=6&-KTJ=#\?XOX6S[Q!XLP'#^=8+ZEX5Y#'
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MV;^U>3SR?VB?B^?7_J<,<<=?QXKQ8> ^:SM_POY>FU_T"XGR_O>?_ /1J_2
MRBEOP]F3],5A>U_Y3_5>HK_*WB_;P_;B)7/[9?[5IX'7]H?XNGT_ZG"M:+]N
MO]MTD9_;'_:I/3_FX7XN'_W;L?Y],UUP^CYG$[?\9%EJO;_F$Q3W_P"WD>;5
M^DGDE+?AK-7Z8S">7]WS/]3*BO\ +B@_;G_;:.,_MA_M3GZ_M!_%H^OKXN_&
MM6+]N/\ ;6(7/[8'[49Y'7]H#XL'T_ZFVNN'T<LYG;_C),L5[?\ ,'BNO_;Y
MYE3Z4N0TKWX5S=V[8W!>7]WS/]0BBO\ ,-A_;?\ VTB1G]KW]J \#K\?OBM[
M_P#4VG_/MBM:#]MO]L\]?VNOVGCP.OQ\^*W_ ,U?^?K73#Z-&=R_YJ?*U_W)
M8M]O[ZZ,\ZI]+;AZG_S2.<NW;'X%?^V^3/\ 3<HK_,XA_;7_ &RR!G]K?]IL
M_7X]?%0]O^QKK8A_;3_;')3/[67[3!R>_P =_BD?7_J:JZX?1>SR>W%65+_N
M1QGE_?\ ,\RK],CANE=/@S/&U_U,, NW>'GV/]*^BO\ -DA_;/\ VPSG/[5_
M[2IZ]?CK\43Z?]336I!^V7^U^1S^U9^TD>._QS^)Y]/^IHKJA]%3/I?\U9E"
MV_Y@,9W7_3SS//J_39X8I/7@?/GZ9CEWE_<\S_2'HK_./B_;&_:[.,_M4?M'
MG.>OQP^)WK_V,]:L'[8?[6Y//[4O[1GX_&[XF>WKXF-=4/HEY_-)KB_)U>W_
M #+\;UM_T\\SS:OTZN%:6_ ?$#?EF>6^7_3L_P!%NBO\[N#]K_\ :T.<_M1?
MM%'GO\;/B5[\?\C,3_7T[&M2']KO]K XS^T]^T.?K\:OB2>__8RDUU0^B!Q#
M/_FLLF6W_,NQW7_N(>;5^GYPE2W\/^(WZ9KEO>W6F?Z&%%?Y\\/[7'[5IQ_Q
MDW^T)_#_ ,UH^(__ ,TE:L/[6G[5)QG]IC]H(\CK\9OB,>Y_ZF3_ #WKKA]#
M;B.=O^,TR57M_P RW'=?^XIYU;]H;PA2W\.N)9?]U?*UV_Z=>9_H!T5_ E#^
MUA^U,<9_:5^/Q^[U^,?Q$/U_YF.M$?M7?M28'_&2?Q]Z?]%B^(G_ ,T=="^A
M=Q(_^:WR3_PV8_R?_/WS^\\V?[1_@R#L_#7B=Z_]#C*O+_IT?WN45_!)_P -
M7?M1_P#1R?Q]_P##Q?$3_P":.C_AJ[]J/_HY/X^_^'B^(G_S1T_^)+>)/^BW
MR3_PV8__ .6^O]/2/^*D7!G_ $;3BC_P\95_\J]?Z>G][=%?P2?\-7?M1_\
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M-.,DVFFFG8U****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ^/?VL/V'/V2OVO?#%Y:_M&? ?P)\2[NQL1_9WB6]L[O0?'>E16+-=P6
MFD?$3PG>Z#X[TG3S.-USING>([6PO4+0WMM<0LT9_"C4_P#@CA_P3?M-0NH;
M?]G/RXXII$1?^%O?'=]JK(P R_Q/9CCU))]3117T>3YYG6!IRP^"SC-,'03<
ME0PN88O#T5)M7DJ=*K""D^KY;L\/,\BR3,*BKX_)LJQU?X?;8S+L)B:O*EI'
MVE:C.=ET5[(JK_P1_P#^"=2?=_9XQSG_ )*U\<S_ #^)AJ>/_@D/_P $\%(
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MT_YG6K/_  [W_9 _Z)%_Y?WQ/_\ FUHHKICX@\?6_P"2WXOZ?\U+G/\ *O\
MJ-.%^#?A"]7X5>&[?GP-PP__ 'EA_P .]_V0?^B1?^7]\3__ )M:/^'>_P"R
M#_T2+_R_OB?_ /-K115?\1!X^_Z+?B__ ,27.?\ YM%_Q!KP@_Z-3X;?^(-P
MQ_\ .L/^'>_[(/\ T2+_ ,O[XG__ #:T?\.]_P!D'_HD7_E_?$__ .;6BBC_
M (B#Q]_T6_%__B2YS_\ -H?\0:\(/^C4^&W_ (@W#'_SK#_AWO\ L@_]$B_\
MO[XG_P#S:T?\.]_V0?\ HD7_ )?WQ/\ _FUHHH_XB#Q]_P!%OQ?_ .)+G/\
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A"X7#4(*E0P^&P]&,*5"A1I1C3I4J4(TZ=.,80BHI(__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
